The present invention provides CD20-binding proteins that bind to and rapidly internalize CD20 antigens from a cell surface location to the interior of a cell. CD20-binding proteins of the invention comprise a CD20 binding region and a Shiga toxin effector region. Certain of the disclosed CD20-binding proteins kill cells that express CD20 on their surface. Further, the presently disclosed CD20-binding proteins can comprise additional exogenous materials and are capable of targeted delivery of these additional exogenous materials into the interior of CD20 expressing cells. Such additional materials may include peptides, antigens, enzymes, and polynucleotides. These CD20-binding proteins have uses in methods of internalizing themselves, targeted killing of CD20 expressing cells, delivering exogenous materials into CD20 expressing cells, and treating a variety of diseases involving CD20 expressing cells, such as cancers and immune disorders.

In one aspect, the present invention is directed to a method for preventing or treating necrotic enteritis by administering a hyperimmunized egg product obtained from an egg-producing animal to an avian. The hyperimmunized egg product may contain an antibody specific to an antigen selected from the group consisting of Clostridium perfringens -toxin, Clostridium perfringens elongation factor Tu (EF-Tu), Clostridium perfringens necrotic enteritis B-like (NetB) toxin, Clostridium perfringens Pyruvate: Ferredoxin oxidoreductase (PFO), and Eimeria tenella elongation factor 1-alpha.

In one aspect, the present invention is directed to a method for preventing or treating necrotic enteritis by administering a hyperimmunized egg product obtained from an egg-producing animal to an avian. The hyperimmunized egg product may contain an antibody specific to an antigen selected from the group consisting of Clostridium perfringens -toxin, Clostridium perfringens elongation factor Tu (EF-Tu), Clostridium perfringens necrotic enteritis B-like (NetB) toxin, Clostridium perfringens Pyruvate: Ferredoxin oxidoreductase (PFO), and Eimeria tenella elongation factor 1-alpha.

The present invention relates to methods and compositions for preventing, treating and diagnosing infection by trypanosomes. The invention also relates to the use of excreted/secreted antigens (exoantigens, secretome) and specifically to the identification of a protein excreted/secreted by the trypanosomes, the inhibition of which makes it possible to provide effective protection, mainly by vaccination, against infection by trypanosomes or the development or spread thereof. The invention relates to use of the protein, the derivatives thereof, a nucleotide sequence derived from said protein, or an extract enriched with said protein, and to the use of antibodies directed against said trypanosomes for immunotherapy, diagnosis, and monitoring of infections by trypanosomes.

The present invention relates to methods and compositions for preventing, treating and diagnosing infection by trypanosomes. The invention also relates to the use of excreted/secreted antigens (exoantigens, secretome) and specifically to the identification of a protein excreted/secreted by the trypanosomes, the inhibition of which makes it possible to provide effective protection, mainly by vaccination, against infection by trypanosomes or the development or spread thereof. The invention relates to use of the protein, the derivatives thereof, a nucleotide sequence derived from said protein, or an extract enriched with said protein, and to the use of antibodies directed against said trypanosomes for immunotherapy, diagnosis, and monitoring of infections by trypanosomes.

Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein and neutralize P. falciparum are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.

This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of P. falciparum circumsporozoite protein (CSP), and the antibodies provided in this disclosure can prevent cleavage and inhibit P. falciparum sporozoites from invading the liver.

The present invention encompasses a vaccine composition and method of use for treating heartworm infestation in mammals. The vaccine composition includes chimeric antigens engineered and manufactured using the genetic code (i.e., the amino acid or protein sequence) of the target sequence. After introduction of the vaccine composition containing the target antigen into the host (e.g., a canine), the host will generate antibodies as part of its robust immune response to the antigen. As the antibodies circulate through the host's plasma, heartworm larvae will consume the antibodies as they feed on the plasma. The antibodies will then act on internal targets of the worm recognized as antigens.

The present invention encompasses a vaccine composition and method of use for treating heartworm infestation in mammals. The vaccine composition includes chimeric antigens engineered and manufactured using the genetic code (i.e., the amino acid or protein sequence) of the target sequence. After introduction of the vaccine composition containing the target antigen into the host (e.g., a canine), the host will generate antibodies as part of its robust immune response to the antigen. As the antibodies circulate through the host's plasma, heartworm larvae will consume the antibodies as they feed on the plasma. The antibodies will then act on internal targets of the worm recognized as antigens.

The present invention relates to a polypeptide consisting of an amino acid sequence selected from: (a) the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8, (b) an amino acid sequence that differs from the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8 by substitution, deletion, addition, or insertion of 1 to 10, preferably 1-5, more preferably 1, 2 or 3 amino acids, and (c) an amino acid sequence that has at least 95%, preferably 97%, more preferably 99% sequence identity with the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8, and a malaria vaccine comprising the polypeptide, for example.